Lacosamide for the prevention of partial onset seizures in epileptic adults

Anna Kelemen1, P&eacute;ter Hal&aacute;sz21National Institute of Neurosciences, Epilepsy Center, Budapest, Hungary; 2Faculty of Information Technology, P&aacute;zm&aacute;ny P&eacute;ter Catholic University, Budapest, Hungary Abstract: Lacosamide is a newly re...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anna Kelemen, P&eacute;ter Hal&aacute;sz
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/56c1ce2899e84c369f380d92a5d28782
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:56c1ce2899e84c369f380d92a5d28782
record_format	dspace
spelling	oai:doaj.org-article:56c1ce2899e84c369f380d92a5d287822021-12-02T02:12:36ZLacosamide for the prevention of partial onset seizures in epileptic adults1176-63281178-2021https://doaj.org/article/56c1ce2899e84c369f380d92a5d287822010-07-01T00:00:00Zhttp://www.dovepress.com/lacosamide-for-the-prevention-of-partial-onset-seizures-in-epileptic-a-a4917https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Anna Kelemen1, P&eacute;ter Hal&aacute;sz21National Institute of Neurosciences, Epilepsy Center, Budapest, Hungary; 2Faculty of Information Technology, P&aacute;zm&aacute;ny P&eacute;ter Catholic University, Budapest, Hungary Abstract: Lacosamide is a newly registered antiepileptic drug with dual mechanisms of action. It selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing. It also binds to a collapsing-response mediator protein-2, CRMP2. Lacosamide has a favorable pharmacokinetic profile; is rapidly and completely absorbed, has a relatively long elimination half-life of 13 hours which allows twice-daily administration, linear pharmacokinetics, and has low potential for drug interactions and renal elimination. Both oral and intravenous formulations of lacosamide are being developed. In placebo-controlled clinical trials, lacosamide was effective in seizure reduction as adjunctive therapy in patients with uncontrolled partial-onset seizures. Lacosamide was generally well tolerated. The most frequently reported adverse events in placebo-controlled trials were dizziness, headache, nausea, and diplopia. Intravenous lacosamide has a comparably good safety profile.Keywords: lacosamide, epilepsy, partial onset seizures Anna KelemenP&eacute;ter Hal&aacute;szDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 465-471 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Anna Kelemen P&eacute;ter Hal&aacute;sz Lacosamide for the prevention of partial onset seizures in epileptic adults
description	Anna Kelemen1, P&eacute;ter Hal&aacute;sz21National Institute of Neurosciences, Epilepsy Center, Budapest, Hungary; 2Faculty of Information Technology, P&aacute;zm&aacute;ny P&eacute;ter Catholic University, Budapest, Hungary Abstract: Lacosamide is a newly registered antiepileptic drug with dual mechanisms of action. It selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing. It also binds to a collapsing-response mediator protein-2, CRMP2. Lacosamide has a favorable pharmacokinetic profile; is rapidly and completely absorbed, has a relatively long elimination half-life of 13 hours which allows twice-daily administration, linear pharmacokinetics, and has low potential for drug interactions and renal elimination. Both oral and intravenous formulations of lacosamide are being developed. In placebo-controlled clinical trials, lacosamide was effective in seizure reduction as adjunctive therapy in patients with uncontrolled partial-onset seizures. Lacosamide was generally well tolerated. The most frequently reported adverse events in placebo-controlled trials were dizziness, headache, nausea, and diplopia. Intravenous lacosamide has a comparably good safety profile.Keywords: lacosamide, epilepsy, partial onset seizures
format	article
author	Anna Kelemen P&eacute;ter Hal&aacute;sz
author_facet	Anna Kelemen P&eacute;ter Hal&aacute;sz
author_sort	Anna Kelemen
title	Lacosamide for the prevention of partial onset seizures in epileptic adults
title_short	Lacosamide for the prevention of partial onset seizures in epileptic adults
title_full	Lacosamide for the prevention of partial onset seizures in epileptic adults
title_fullStr	Lacosamide for the prevention of partial onset seizures in epileptic adults
title_full_unstemmed	Lacosamide for the prevention of partial onset seizures in epileptic adults
title_sort	lacosamide for the prevention of partial onset seizures in epileptic adults
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/56c1ce2899e84c369f380d92a5d28782
work_keys_str_mv	AT annakelemen lacosamideforthepreventionofpartialonsetseizuresinepilepticadults AT pampeacuteterhalampaacutesz lacosamideforthepreventionofpartialonsetseizuresinepilepticadults
_version_	1718402595445276672

Lacosamide for the prevention of partial onset seizures in epileptic adults

Ejemplares similares